Cargando…
Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study
BACKGROUND: Patients on immunosuppressive drugs have been excluded from COVID-19 vaccines trials, creating concerns regarding their efficacy. AIMS: To explore the humoral response to COVID-19 vaccines in patients with inflammatory bowel disease (IBD) METHODS: Effectiveness and Safety of COVID-19 Vac...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420701/ https://www.ncbi.nlm.nih.gov/pubmed/36127228 http://dx.doi.org/10.1016/j.dld.2022.08.027 |
_version_ | 1784777446862618624 |
---|---|
author | Macaluso, Fabio Salvatore Principi, Mariabeatrice Facciotti, Federica Contaldo, Antonella Todeschini, Alessia Saibeni, Simone Bezzio, Cristina Castiglione, Fabiana Nardone, Olga Maria Spagnuolo, Rocco Fantini, Massimo Claudio Riguccio, Gaia Caprioli, Flavio Viganò, Chiara Felice, Carla Fiorino, Gionata Correale, Carmen Bodini, Giorgia Milla, Monica Scardino, Giulia Vernero, Marta Desideri, Federico Mannino, Mariella Rizzo, Giuseppe Orlando, Ambrogio |
author_facet | Macaluso, Fabio Salvatore Principi, Mariabeatrice Facciotti, Federica Contaldo, Antonella Todeschini, Alessia Saibeni, Simone Bezzio, Cristina Castiglione, Fabiana Nardone, Olga Maria Spagnuolo, Rocco Fantini, Massimo Claudio Riguccio, Gaia Caprioli, Flavio Viganò, Chiara Felice, Carla Fiorino, Gionata Correale, Carmen Bodini, Giorgia Milla, Monica Scardino, Giulia Vernero, Marta Desideri, Federico Mannino, Mariella Rizzo, Giuseppe Orlando, Ambrogio |
author_sort | Macaluso, Fabio Salvatore |
collection | PubMed |
description | BACKGROUND: Patients on immunosuppressive drugs have been excluded from COVID-19 vaccines trials, creating concerns regarding their efficacy. AIMS: To explore the humoral response to COVID-19 vaccines in patients with inflammatory bowel disease (IBD) METHODS: Effectiveness and Safety of COVID-19 Vaccine in Patients with Inflammatory Bowel Disease (IBD) Treated with Immunomodulatory or Biological Drugs (ESCAPE-IBD) is a prospective, multicentre study promoted by the Italian Group for the study of Inflammatory Bowel Disease. We present data on serological response eight weeks after the second dose of COVID-19 vaccination in IBD patients and healthy controls (HCs). RESULTS: 1076 patients with IBD and 1126 HCs were analyzed. Seropositivity for anti-SARS-CoV-2 IgG was reported for most IBD patients, even if with a lesser rate compared with HCs (92.1% vs. 97.9%; p<0.001). HCs had higher antibody concentrations (median OD 8.72 [IQR 5.2-14-2]) compared to the whole cohort of IBD patients (median OD 1.54 [IQR 0.8-3.6]; p<0.001) and the subgroup of IBD patients (n=280) without any treatment or on aminosalicylates only (median OD 1.72 [IQR 1.0–4.1]; p<0.001). CONCLUSIONS: Although most IBD patients showed seropositivity after COVID-19 vaccines, the magnitude of the humoral response was significantly lower than in HCs. Differently from other studies, these findings seem to be mostly unrelated to the use of immune-modifying treatments (ClinicalTrials.govID:NCT04769258). |
format | Online Article Text |
id | pubmed-9420701 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94207012022-08-30 Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study Macaluso, Fabio Salvatore Principi, Mariabeatrice Facciotti, Federica Contaldo, Antonella Todeschini, Alessia Saibeni, Simone Bezzio, Cristina Castiglione, Fabiana Nardone, Olga Maria Spagnuolo, Rocco Fantini, Massimo Claudio Riguccio, Gaia Caprioli, Flavio Viganò, Chiara Felice, Carla Fiorino, Gionata Correale, Carmen Bodini, Giorgia Milla, Monica Scardino, Giulia Vernero, Marta Desideri, Federico Mannino, Mariella Rizzo, Giuseppe Orlando, Ambrogio Dig Liver Dis Alimentary Tract BACKGROUND: Patients on immunosuppressive drugs have been excluded from COVID-19 vaccines trials, creating concerns regarding their efficacy. AIMS: To explore the humoral response to COVID-19 vaccines in patients with inflammatory bowel disease (IBD) METHODS: Effectiveness and Safety of COVID-19 Vaccine in Patients with Inflammatory Bowel Disease (IBD) Treated with Immunomodulatory or Biological Drugs (ESCAPE-IBD) is a prospective, multicentre study promoted by the Italian Group for the study of Inflammatory Bowel Disease. We present data on serological response eight weeks after the second dose of COVID-19 vaccination in IBD patients and healthy controls (HCs). RESULTS: 1076 patients with IBD and 1126 HCs were analyzed. Seropositivity for anti-SARS-CoV-2 IgG was reported for most IBD patients, even if with a lesser rate compared with HCs (92.1% vs. 97.9%; p<0.001). HCs had higher antibody concentrations (median OD 8.72 [IQR 5.2-14-2]) compared to the whole cohort of IBD patients (median OD 1.54 [IQR 0.8-3.6]; p<0.001) and the subgroup of IBD patients (n=280) without any treatment or on aminosalicylates only (median OD 1.72 [IQR 1.0–4.1]; p<0.001). CONCLUSIONS: Although most IBD patients showed seropositivity after COVID-19 vaccines, the magnitude of the humoral response was significantly lower than in HCs. Differently from other studies, these findings seem to be mostly unrelated to the use of immune-modifying treatments (ClinicalTrials.govID:NCT04769258). Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. 2023-02 2022-08-29 /pmc/articles/PMC9420701/ /pubmed/36127228 http://dx.doi.org/10.1016/j.dld.2022.08.027 Text en © 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Alimentary Tract Macaluso, Fabio Salvatore Principi, Mariabeatrice Facciotti, Federica Contaldo, Antonella Todeschini, Alessia Saibeni, Simone Bezzio, Cristina Castiglione, Fabiana Nardone, Olga Maria Spagnuolo, Rocco Fantini, Massimo Claudio Riguccio, Gaia Caprioli, Flavio Viganò, Chiara Felice, Carla Fiorino, Gionata Correale, Carmen Bodini, Giorgia Milla, Monica Scardino, Giulia Vernero, Marta Desideri, Federico Mannino, Mariella Rizzo, Giuseppe Orlando, Ambrogio Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study |
title | Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study |
title_full | Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study |
title_fullStr | Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study |
title_full_unstemmed | Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study |
title_short | Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study |
title_sort | reduced humoral response to two doses of covid-19 vaccine in patients with inflammatory bowel disease: data from escape-ibd, an ig-ibd study |
topic | Alimentary Tract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420701/ https://www.ncbi.nlm.nih.gov/pubmed/36127228 http://dx.doi.org/10.1016/j.dld.2022.08.027 |
work_keys_str_mv | AT macalusofabiosalvatore reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy AT principimariabeatrice reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy AT facciottifederica reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy AT contaldoantonella reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy AT todeschinialessia reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy AT saibenisimone reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy AT bezziocristina reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy AT castiglionefabiana reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy AT nardoneolgamaria reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy AT spagnuolorocco reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy AT fantinimassimoclaudio reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy AT rigucciogaia reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy AT caprioliflavio reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy AT viganochiara reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy AT felicecarla reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy AT fiorinogionata reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy AT correalecarmen reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy AT bodinigiorgia reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy AT millamonica reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy AT scardinogiulia reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy AT verneromarta reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy AT desiderifederico reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy AT manninomariella reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy AT rizzogiuseppe reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy AT orlandoambrogio reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy AT reducedhumoralresponsetotwodosesofcovid19vaccineinpatientswithinflammatoryboweldiseasedatafromescapeibdanigibdstudy |